<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0905233611
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AMLOHOPE 10 mg/10 mg Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RAMIPRIL,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        50.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EGIS PHARMACEUTICALS PLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EGIS PHARMACEUTICALS PLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HEXAL AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BB07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amlohopecontains 2 active substances, which are called ramipril and amlodipine. Ramipril belongs to the active substance class of ACE inhibitors (angiotensin converting enzyme inhibitors), while amlodipine belongs to the active substance class of the calcium channel blockers.</p><p>&nbsp;</p><p>Ramipril works by</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decreasing your body&rsquo;s production of substances that could raise your blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; making your blood vessels relax and widen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; making it easier for your heart to pump blood around your body.</p><p>&nbsp;</p><p>Amlodipine works by</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; making your blood vessels relax and widen so that the blood can flow through more easily.</p><p>&nbsp;</p><p>Amlohopeis used for the treatment of high blood pressure (hypertension) in patients who are sufficiently adjusted when both active substances are administered as single tablets at the same strength as the combination preparation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Amlohope</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ramipril, amlodipine, another calcium channel blocker, another ACE inhibitor, Azorubine, or any of the other ingredients of this medicine listed in section 6</p><p>Signs of an allergic reaction include rash, swallowing or breathing problems, swelling of the lips, face, throat or tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart failure after heart attack</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have a narrowing of the aortic heart valve (aortic stenosis), or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had a severe allergic reaction, such as angioedema</p><p>The signs include itching, hives (urticaria), red marks on the hands, feet and throat, swelling of the throat and tongue, swelling around the eyes and lips, difficulty breathing and swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are having dialysis or any other type of blood filtration</p><p>Depending on the unit used, treatment with Amlohopemay not be suitable for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a kidney disease where your kidney&rsquo;s blood supply is restricted (renal artery stenosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes mellitus or impaired renal function and are being treated with a blood pressure-lowering drug containing aliskiren</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have taken or are taking sacubitril/valsartan, a medicine for the treatment of chronic heart failure in adults, because this increases the risk of angioedema (rapid swelling under the skin, e.g. in the throat area)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; during the last 6 months of pregnancy (it is recommended not to use Amlohopein the early phase of pregnancy, see section &ldquo;Pregnancy and breastfeeding&rdquo;.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your blood pressure is unusually low or fluctuating</p><p>This should be assessed by your doctor.</p><p>&nbsp;</p><p>Do not take Amlohopeif any of the above applies to you. If you are not sure, ask your doctor before taking Amlohope.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Amlohope</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are elderly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart, liver or kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from acute low blood pressure with a risk of circulatory disorders in the heart or brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your blood pressure is extremely elevated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have lost large amounts of body salts or fluids (due to vomiting, diarrhea, exceptionally strong sweating, a low salt diet, taking diuretics [water tablets] for a long time or if you are a dialysis patient)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if your allergy to bee or wasp sings is being treated (desensitization)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are about to receive an anesthetic</p><p>This may be the case if you are having surgery or at the dentist. It may be necessary to discontinue your treatment with Amlohope1 day before; ask your doctor for advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines, the risk of angioedema (rapid swelling under the skin in areas such as the throat), a serious allergic reaction, is increased:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Racecadotril, a medicine for treating diarrhea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to prevent rejection of transplanted organs or for cancer treatment (e.g. temsirolimus, sirolimus, everolimus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vildagliptin, a medicine for treating diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have high potassium levels in the blood (detectable in blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines or have conditions that can lower the sodium levels in the blood; your doctor may regularly perform blood tests to check the concentration of sodium in your blood, especially if you are elderly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from collagenosis such as scleroderma or systemic lupus erythematosus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have a dark skin color</p><p>You are at higher risk of:</p><p>-&nbsp;&nbsp;&nbsp; sudden, usually painful severe swelling of the deeper skin layers, especially in the face (angioedema)</p><p>-&nbsp;&nbsp;&nbsp; the effect of ramipril being weaker</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have a cough</p><p>Inform your doctor if the cough becomes worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines for the treatment of high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp; an angiotensin II receptor antagonist (these are also called sartans - e.g. valsartan, telmisartan, irbesartan), especially if you have kidney problems due to diabetes mellitus</p><p>-&nbsp;&nbsp;&nbsp; Aliskiren</p><p>If necessary, your doctor will check your kidney function, blood pressure and electrolyte levels (e.g. potassium) in your blood at regular intervals.</p><p>See also the section &ldquo;Do not take Amlohope&rdquo;.</p><p>&nbsp;</p><p>Tell your doctor if you think you are pregnant (<u>or might be pregnant</u>). Taking Amlohopein the early phase of pregnancy is not recommended, and Amlohopemust not be taken after the third month of pregnancy, since Amlohopecan cause serious harm to your unborn child in this stage (see section &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p>&nbsp;</p><p>If any of the above applies to you (or you are not sure), ask your doctor before taking Amlohope.</p><p>&nbsp;</p><p>It is recommended that your doctor monitors your white blood cell count. More frequent tests are recommended</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; at the start of treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; in patients with impaired renal function or collagenosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; when taking medications that affect the blood count.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Amlohopein children and adolescents under 18 years of age is not recommended because there is no information on the safety and efficacy of this medicine for this age group.</p><p>&nbsp;</p><p><strong>Taking Amlohopetogether with other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used, or might take/use any other medicines. Amlohopecan influence the effect of other medicines, or can itself be influenced in its effect by other medicines.</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines. They can weaken the effect of Amlohope :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for pain and inflammation (e.g. non-steroidal anti-inflammatory drugs [NSAIDs] such as ibuprofen, indomethacin or acetylsalicylic acid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for the treatment of low blood pressure, shock, heart failure, asthma or allergies such as ephedrine, noradrenaline, adrenaline, isoproterenol, dobutamine or dopamine</p><p>Your doctor will have to check your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (herbal medicine for treating depression)</p><p>&nbsp;</p><p>Inform your doctor if you are taking any of the following medicines, since taking these simultaneously with Amlohopeincreases the risk of side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for pain and inflammation (e.g. non-steroidal anti-inflammatory drugs [NSAIDs] such as ibuprofen, indomethacin and acetylsalicylic acid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for cancer (chemotherapy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Temsirolimus (to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that are used very often to prevent rejection of organ transplants (sirolimus, everolimus, and other drugs belonging to the class of mTOR inhibitors). See section &ldquo;Warnings and Precautions&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sacubitril/valsartan (for the treatment of heart failure)</p><p>Do not take Amlohopeif you are currently taking sacubitril/valsartan or have taken it in the past (see &ldquo;Do not take Amlohope&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics (water tablets) such as furosemide</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that reduce blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may need to adjust your dosage and/or take other precautionary measures:</p><p>if you are taking an angiotensin II receptor antagonist or aliskiren (see also sections &ldquo;Do not take Amlohope&rdquo; and &ldquo;Warnings and Precautions&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Erythromycin, clarithromycin (antibiotics)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Potassium supplements (including salt substitutes), potassium-sparing diuretics (a certain group of water tablets such as spironolactone, triamteride, or amiloride) and other medicines that can increase the potassium level in the blood, such as trimethoprim and co-trimoxazole, also known as trimethoprim/sulfamethoxazole, against bacterial infections; ciclosporin and tacrolimus, medicines for suppressing the immune system to prevent rejection of transplanted organs; and heparin, a medicine for blood thinning and avoiding blood clots)</p><p>If you take these medicines at the same time, close monitoring of potassium levels in the blood is required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Steroid-containing medicines for inflammation such as prednisolone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Allopurinol (to reduce uric acid levels in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Procainamide (to treat heart rhythm disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that can affect blood counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, itraconazole (for the treatment of fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Ritonavir, indinavir, nelfinavir (for the treatment of HIV-infected patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dantrolene (for infusion in the case of severe body temperature disorders [hyperthermia])</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Vildagliptin (to treat type 2 diabetes mellitus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Racecadotril (to treat diarrhea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil, diltiazem (to treat certain heart diseases and high blood pressure)</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines. They can be influenced by Amlohope:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for diabetes such as blood sugar-lowering medicines for oral use and insulin</p><p>Amlohopecan lower your blood sugar level. Blood sugar levels must therefore be closely monitored while taking Amlohope.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (to treat mental illness)</p><p>Amlohopecan increase the lithium concentration in the blood. Your doctor will therefore have to monitor your lithium levels closely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Simvastatin (cholesterol-lowering medicines): Amlodipine increases the availability (exposure) of simvastatin. Your doctor will have to reduce the simvastatin dose if you take Amlohope.</p><p>&nbsp;</p><p>If any of the above applies to you (or you are not sure), ask your doctor before taking Amlohope.</p><p>&nbsp;</p><p><strong>Taking Amlohopewith food, drink and alcohol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Patients who take Amlohopeshould not drink grapefruit juice or eat grapefruit because the blood levels of the active substance amlodipine may be increased as a result, which can lead to an uncontrolled increase in the blood pressure-lowering effect of Amlohope.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol consumption while taking Amlohope can cause dizziness and drowsiness. If you are unsure about the amount of alcohol you are allowed to drink while taking Amlohope, ask your doctor, as blood pressure-lowering agents and alcohol can increase the effect of both.</p><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding</strong></p><p>Tell your doctor if you think you are pregnant (<u>or might be pregnant</u>). As a rule, your doctor will recommend that you discontinue Amlohopebefore a pregnancy or as soon as you know that you are pregnant, and will recommend another medicine. Taking Amlohopein the early phase of pregnancy is not recommended and Amlohopemust not be taken after the third month of pregnancy, since Amlohopecan cause serious damage to your unborn child in this stage.</p><p>&nbsp;</p><p>Inform your doctor immediately if you become pregnant during treatment with Amlohope.</p><p>&nbsp;</p><p>Switching to another suitable treatment should take place before a planned pregnancy.</p><p>&nbsp;</p><p>Tell your doctor if you are breastfeeding or would like to begin breastfeeding. Taking Amlohopeis not recommended for breastfeeding mothers. Your doctor may choose a different treatment for you if you wish to breastfeed, particularly if your child has just been born or if it was born prematurely.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking or using any medicine.</p><p>&nbsp;</p><p><strong>Effects on ability to drive and use machines</strong></p><p>Amlohopecan impair the ability to drive or use machines.</p><p>You may feel unwell, dizzy, tired or have headaches while taking Amlohope. The probability is highest at the start of treatment with Amlohopeor if you increase the dose. In this case, you must not drive and operate any tools or machines.</p><p>&nbsp;</p><p><strong>Amlohopecontains Azorubine (E 122)</strong></p><p>Azorubine (E 122) can cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Only use this medicine exactly as your doctor has instructed. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking the medicine </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine at the same time every day, at or in between mealtimes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the hard capsules whole with liquid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not crush or chew the hard capsules.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not take this medicine with grapefruit juice.</p><p>&nbsp;</p><p><strong>Dosing </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 1 hard capsule of the strength prescribed by the doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Depending on the effect, your doctor will increase or adjust the dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The maximum dose is 1 hard capsule of strength 10 mg/10 mg once daily.</p><p><u>&nbsp;</u></p><p><u>Elderly patients</u><u> </u></p><p>Your doctor will reduce your initial dose and slowly adjust the treatment. Administration of Amlohope hard capsules is not recommended in very old and frail patients.</p><p><em>&nbsp;</em></p><p><u>Use in the children and adolescents</u></p><p>The use of Amlohopein children and adolescents under 18 years of age is not recommended, as there is insufficient data on safety and efficacy.</p><p>&nbsp;</p><p>If you have the impression that the effect of the medicine is too strong or too weak, talk to your doctor.</p><p>&nbsp;</p><p><strong>If you take more Amlohopethan you should</strong></p><p>If you have taken too many capsules, your blood pressure may drop or even become dangerously low. You may feel dizzy, light-headed and weak or faint. If the drop in blood pressure is strong enough, it can lead to shock. Your skin can feel cold and moist and you could lose consciousness. Consult a doctor or go to the accident and emergency department of the nearest hospital. Do not drive to the hospital yourself, but ask another person to do so or call a ambulance. Take the pack of the medicine so that the doctor knows what you have taken.</p><p>&nbsp;</p><p><strong>If you forget to take Amlohope</strong></p><p>If you have missed a dose, take the next dose at the next scheduled time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Amlohope</strong></p><p>Do not stop the treatment abruptly and do not change the prescribed dose without consulting your treating physician, as your illness might worsen temporarily.</p><p>&nbsp;</p><p>If you have further questions on the use of this medicine, contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop taking Amlohopeimmediately and contact your doctor without delay</strong> if you notice any of the following serious side effects - you may need urgent medical treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, or throat that causes difficulty swallowing or breathing, as well as itching and skin rashes</p><p>This can be a sign of a severe hypersensitivity reaction to this drug.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin reactions including skin rash, ulcers in the mouth, rash with blisters on lips, eyes and mouth, worsening of pre-existing skin diseases, redness, severe itching, blistering, scaling and swelling of the skin, inflammation of the mucous membranes (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) or allergic reactions.</p><p>&nbsp;</p><p><strong>Inform your doctor immediately if you experience: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Accelerated heart rate, irregular or strong heartbeat (palpitations), irregular or slow heartbeat, pain or tightness in the chest (angina pectoris) or serious events such as heart attack or stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (difficulty breathing or wheezing) or coughing</p><p>These are possible signs of lung disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Bruising more easily, bleeding that lasts longer than normal, any signs of bleeding (e.g. bleeding gums), purple spots on the skin or increased infection susceptibility, sore throat and fever, fatigue, weakness, dizziness, or pale skin</p><p>These are possible signs of a blood or bone marrow disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe abdominal pain that can radiate up the back</p><p>These are possible signs of pancreatic inflammation (pancreatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fever, chills, fatigue, loss of appetite, abdominal pain, nausea, dark urine, yellowing of the skin or eyes (jaundice)</p><p>These are possible signs of liver diseases such as liver inflammation (hepatitis) or liver damage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severely reduced urine excretion, swelling, loss of appetite, nausea, vomiting, fatigue, difficulty breathing, unusual heart rhythm</p><p>This could be a sign of severe kidney disease.</p><p>&nbsp;</p><p><strong>Other possible side effects </strong></p><p><strong>Very common:</strong>&nbsp;may affect more than 1 in 10 patients treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (edema)</p><p><strong>&nbsp;</strong></p><p><strong>Common:</strong>&nbsp;may affect up to 1 in 10 patients treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness (especially at the start of treatment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations (perception of the heart beat), reddening of the skin (flush)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swollen ankles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Headache or feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>The probability of this is highest at the start of treatment with Ramipril HEXAL plus Amlodipine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fainting (syncope), hypotension (unusually low blood pressure), especially when you get up or stand up quickly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Vision disorders (including double vision)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dry cough, sinus inflammation (sinusitis) or bronchitis, shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Stomach or intestinal pain, altered bowel movements (including diarrhea and constipation), abdominal discomfort, digestive disorders, feeling unwell or vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Stomach and/or intestinal inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash with or without skin irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps or pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased potassium levels in the blood</p><p>&nbsp;</p><p><strong>Uncommon:</strong>&nbsp;may affect up to 1 in 100 patients treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Mood swings, depressed mood, anxiety, unusual nervousness or restlessness, sleep disorders (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Trembling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Vision disturbance (including blurred vision)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sneezing/runny nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Itching (pruritus), generalized skin rash, purple spots on the skin (purpura), skin discoloration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Disorders in urinary excretion, more frequent urinary excretion during the day than usual, especially at night, worsening of existing proteinuria (higher protein levels in urine than usual)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unwell,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Backache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain or loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Enlargement of the mammary glands in men</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Spinning sensation (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Itching and unusual skin sensations such as numbness, prickling, stinging, burning or tingling on your skin (paresthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Decreased sensitivity of the skin (hypesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Loss or change in taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Blocked nose, difficulty breathing or wheezing, worsening of asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in the intestine, intestinal angioedema with symptoms such as abdominal pain, vomiting and diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatic inflammation (pancreatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain, nausea (gastritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Loss of or reduction in appetite (anorexia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swollen arms and legs</p><p>These are possible signs of fluid accumulation in the body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sexual disorders in men, decreased sexual desire in men and women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the number of specific white blood cells (eosinophilia) (detected in a blood test)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Blood values suggestive of liver, pancreas or kidney function disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack, disease of the blood vessels of the heart (myocardial ischemia), tightness and pain in the chest (angina pectoris), rapid, irregular or slow heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips or throat (see advice at the beginning of section 4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Reduced kidney function, including severe kidney disease (acute kidney failure) (see advice at the beginning of section 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pain</p><p>&nbsp;</p><p><strong>Rare:</strong>&nbsp;may affect up to 1 in 1,000 patients treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of confusion or being confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Balance disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Red and swollen tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe scaling or detachment of the skin, itchy, raised skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Nail problems (e.g. loosening or detachment of nail from the nail bed)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash or bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Spots on the skin and cold extremities</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Red, itchy, swollen or teary eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hearing disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of red blood cells, white blood cells or platelets, too low hemoglobin value in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Narrowing of blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin (cholestatic jaundice), liver cell damage</p><p>&nbsp;</p><p><strong>Very rare:</strong>&nbsp;may affect up to 1 in 10,000 patients treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Liver inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased sun sensitivity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood sugar levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased muscle tension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Nerve disorder which can cause muscle weakness, tingling or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gingival proliferation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin reactions (see advice at the beginning of section 4.)</p><p>&nbsp;</p><p><strong>Additional reported side effects </strong>(frequency cannot be estimated based on the available data)</p><p>Inform your doctor if any of the listed side effects affects you significantly or lasts more than a few days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty concentrating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the oral mucosa with small ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Blood count with too few blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Too low sodium levels in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Discoloration of fingers and toes when cold, and tingling or pain when warming up (Raynaud&rsquo;s syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Slowed or deteriorated ability to react</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Burning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Altered sense of smell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Thickened spots of red/silver skin (psoriasis) or rash with silver-colored appearance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash on the mucosa (enanthema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Bone marrow insufficiency</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Circulation disorders in the brain including stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increase in number of certain antibodies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Concentrated urine (dark color), nausea or vomiting, muscle cramps, confusion and seizures which may be caused by inappropriate ADH (antidiuretic hormone) secretion. Contact your doctor immediately if these symptoms occur.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Trembling, rigid posture, mask-like face, slow movements and shuffling, unbalanced gait</p><p>&nbsp;</p><p>Azorubine (E 122) can cause allergic reactions.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you notice any side effects, please contact your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep this medicine out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Do not use this medicine after the expiration date which is stated on the outer carton and the blister pack after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>You must not use this medicine if you notice visible signs of non-usability (e.g. discoloration).</p><p>&nbsp;</p><p>Never dispose of medicines via the waste water (e.g. not down the toilet or the sink). Ask your pharmacist how to dispose of medicines you no longer use. This helps to protect the environment. For more information, please visit www.bfarm.de/arzneimittelentsorgung.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are:</p><p>Each hard capsule contains 10 mg ramipril and 10 mg amlodipine (as amlodipine besilate 13.9 mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><em>Capsule filling:</em> Crospovidone, hypromellose, microcrystalline cellulose, glycerol dibehenate (Ph.Eur.)</p><p><em>Capsule base and capsule cap:</em> Indigo carmine (E 132), azorubine (E 122), titanium dioxide (E 171), gelatin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Amlohopeare unmarked, self-closing Coni-Snap size 0 hard gelatin capsules with an opaque red/brown-colored capsule base and an opaque red/brown-colored capsule cap. Filled with white or almost white, odorless or almost odorless granulate powder without mechanical impurities.
	
	Amlohopeis available in packs of 10, 20, 30, 50, 90 or 100 hard capsules in blister packs in a carton. 
	
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Hexal AG</p><p>Industriestra&szlig;e 25</p><p>83607 Holzkirchen</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Lek Pharmaceuticals d.d.</p><p>Verov&scaron;kova 57</p><p>1526 Ljubljana</p><p>Slovenia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	06/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار أملوهوب على مادتين فعالتين، تُدعيان راميبريل وأملوديبين. ينتمي راميبريل إلى المواد الفعالة من فئة مُثبطات إنزيم تحويل الأنجيوتنسين، بينما يَنتمي أملوديبين إلى المواد الفعالة من فئة حاصرات قنوات الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل راميبريل من خلال الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تقليل إنتاج جسمك للمواد التي قد ترفع ضغط الدَّم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إرخاء أوعيتك الدموية وتوسيعها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضخ القلب للدم إلى جميع أجزاء الجسم بشكل أكثر سهولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل أملوديبين من خلال الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إرخاء الأوعية الدَّموية لديك وتوسعتها وبالتالي يمكن للدَّم أن يتدفق بسهولة أكبر.</p><p dir="RTL">&nbsp;</p><p>يُستخدم عقار أملوهوب لعلاج ارتفاع ضغط الدَّم في المرضى ممن يتم ضبط ضغط الدَّم لديهم بشكل كاف عند إعطائهم كلا المادتين الفعَّالتين على هيئة أقراص مفردة بنفس تركيز المستحضر المُركب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار أملوهوب في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه راميبريل أو أملوديبين أو أي حاصر آخر لقنوات الكالسيوم أو أي مثبط آخر للإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ أو أزوروبين أو أي مكون من المكونات الأخرى الموجودة بهذا الدَّواء المدرجة في قسم: 6.</p><p dir="RTL">تشمل علامات الإصابة بأحد تفاعلات الحساسية طفحًا جلديًّا، مشاكل في البلع أو التنفس، تورُّم الشفتين، الوجه، الحَلْق أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل القلب بعد التعرض لنوبة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضيُّق بصمام القلب الأورطي أو صدمة قلبية (حالة يكون فيها القلب لديك غير قادر على إمداد الجسم بما يكفي من الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت من قبل بأحد تفاعلات الحساسية الشديدة، مثل: الوذمة الوعائية.</p><p dir="RTL">تشمل العلامات حكة، شرى (أرتكاريا)، علامات حمراء على اليدين، القدمين والحَلْق، تورم الحَلْق واللسان، تورمًا حول العينين والشفتين، صعوبة في التنفس والبلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للغسيل الكلوي أو أي نوع آخر من إجراءات ترشيح الدم.</p><p dir="RTL">بناءً على الوحدة المُستخدمة، قد لا يكون العلاج بعقار أملوهوب مناسبًا لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كُلوي حيث يكون إمداد الدم إلى كليتيك مقيدًا (ضيق الشريان الكلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور بوظائف الكُلى ويتم علاجك بأحد العقاقير الخافضة لضغط الدَّم التي تحتوي على أليسكيرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت أو كنت تتناول ساكوبيتريل/ فالسارتان، وهو دواء يُستخدم لعلاج فشل القلب المزمن في البالغين؛ إذ يزيد ذلك من خطر الإصابة بوذمة وعائية (تورُّم سريع تحت الجلد، على سبيل المثال في منطقة الحلق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خلال الـ6 أشهر الأخيرة من الحمل (يُوصى بعدم استخدام عقار أملوهوب في المرحلة المبكرة من الحمل، انظري قسم &quot;الحمل والرضاعة الطبيعية&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان ضغط الدَّم لديك منخفضًا أو متقلبًا على غير العادة.</p><p dir="RTL">ينبغي أن يخضع ذلك لتقييم طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول عقار أملوهوب إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، استشر طبيبك قبل تناوُل عقار أملوهوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار أملوهوب في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من كبار السن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أحد أمراض القلب أو الكبد أو الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض حاد في ضغط الدَّم مصحوب بخطر الإصابة باضطرابات الدورة الدَّموية في القلب أو المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع شديد في ضغط الدَّم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد فقدت كميات كبيرة من الأملاح أو سوائل الجسم (بسبب القيء، الإسهال، التعرق الشديد بشكل استثنائي، اتباع نظام غذائي قليل الملح، تناول مُدِرات البول [أقراص الماء] لفترة طويلة أو إذا كنت مريضًا تخضع للغسيل الكلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالج من حساسية تجاه لدغات النحل أو الدبابير (إزالة التحسس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على وشك تلقي أحد أدوية التخدير.</p><p dir="RTL">قد يكون هذا هو الحال إذا كنت تخضع لعملية جراحية أو كنت عند طبيب الأسنان. قد يكون من الضروري وقف علاجك بعقار أملوهوب قبل تلقي دواء التخدير بيوم واحد؛ لذا عليك استشارة طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية التَّالية، فتزداد خطورة الإصابة بالوذمة الوعائية (وهي عبارة عن تورُّم سريع تحت الجلد في مناطق مثل الحلق)، والتي تعد أحد تفاعلات الحساسية الخطيرة:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>راسيكادوتريل، وهو دواء يستخدم لعلاج الإسهال.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الأدوية المُستخدمة لمنع رفض الأعضاء المزروعة أو لعلاج السرطان (على سبيل المثال: تيمسيروليموس، سيروليموس، إفيروليموس).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فيلداجليبتن، وهو دواء يستخدم لعلاج مرض السُّكَّرِي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع مستويات البوتاسيوم في الدم (يمكن الكشف عنه من خلال اختبارات الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أو كنت تعاني من حالات مرضية يمكنها خفض مستويات الصوديوم بالدم، قد يجري طبيبك اختبارات بالدَّم بصفة منتظمة؛ للتحقق من تركيز الصوديوم لديك بالدم، خاصةً إذا كنت من كبار السن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء كولَاجينِيّ مثل تصلب الجلد أو الذئبة الحمامية الجهازية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك جلد داكن اللون.</p><p dir="RTL">أنت أكثر عرضة لخطر حدوث الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مفاجئ، عادة ما يكون مؤلمًا وشديدًا بطبقات الجلد العميقة، خاصةً بالوجه (وذمة وعائية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف تأثير راميبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من السعال.</p><p dir="RTL">أبلغ طبيبك إذا تفاقم السعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد مناهضات مستقبلات الأنجيوتنسين-2 (التي تُدعى أيضًا بالسارتانات- على سبيل المثال: فالسارتان، تلميسارتان، إربيسارتان) خاصةً إذا كنت تعاني من مشاكل في الكُلى ناجمة عن الإصابة بمرض السُّكَّرِي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">إذا لزم الأمر، سيقوم طبيبك بفحص وظائف الكُلى وضغط الدَّم ومستويات الكهارل &quot;الإليكتروليتات&quot; (على سبيل المثال: البوتاسيوم) لديك بالدَّم على فترات منتظمة.</p><p dir="RTL">انظر أيضًا قسم: &quot;لا تتناول عقار أملوهوب في الحالات الآتية&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (<u>أو قد تكونين حاملًا</u>). لا يُوصى بتناوُل عقار أملوهوب في المرحلة المبكرة من الحمل ويجب عدم تناوُله بعد الشهر الثالث من الحمل؛ إذ من الممكن أن يُلحق عقار أملوهوب في هذه المرحلة ضررًا جسيمًا بجنينكِ (انظري قسم: &quot;الحمل والرضاعة الطبيعيَّة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا من ذلك)، فاسأل طبيبك قبل تناول عقار أملوهوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى بأن يراقب طبيبك تعداد خلايا الدَّم البيضاء لديك. يُوصى بإجراء المزيد من الاختبارات بشكل متكرر في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عند بدء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; في المرضى المصابين بقصور وظائف الكلى أو يعانون من داء كولَاجينِيّ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عند تناول أدوية تؤثر على تعداد خلايا الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام عقار أملوهوب في الأطفال والمراهقين ممن تقل أعمارهم عن 18 عامًا حيث لا تُوجد أية معلومات حول أمان هذا الدواء وفعاليته لهذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل عقار أملوهوب مع الأدوية الأخرى</strong></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي الخاص بك إذا كنت تتناول/ تستخدم أو تناولت/ استخدمت مؤخرًا أو قد تتناول/ تستخدم أيَّة أدوية أخرى. يمكن أن يؤثر عقار أملوهوب على تأثير الأدوية الأخرى أو قد يتأثر تأثيره بالأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية. فقد تضعف من تأثير عقار أملوهوب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المُخصصة لعلاج الآلام والالتهابات (على سبيل المثال: مضادات الالتهاب غير الستيرويدية مثل: إيبوبروفين، إندوميثاسين أو حمض أسيتيل الساليسيليك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المُخصصة لعلاج انخفاض ضغط الدَّم، الصدمة، فشل القلب، الربو أو حالات الحساسية مثل: إفيدرين، نورادرينالين، أدرينالين، أيزوبروتيرينول، دُوبيوتامِين أو دُوبامِين.</p><p dir="RTL">سيتعين على طبيبك فحص ضغط الدَّم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (أحد المضادات الحيوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (دواء عشبي لعلاج الاكتئاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية؛ لأنَّ تناولها بمصاحبة عقار أملوهوب من شأنه أن يزيد من خطر حدوث الآثار الجانبية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المُخصصة لعلاج الآلام والالتهابات (على سبيل المثال: مضادات الالتهاب غير الستيرويدية مثل: إيبوبروفين، إندوميثاسين وحمض أسيتيل الساليسيليك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المُخصصة لعلاج السرطان (العلاج الكيميائي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تيمسيروليموس (لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم في كثير من الأحيان لمنع رفض الأعضاء المزروعة (سيروليموس، إفيروليموس وغيرهما من العقاقير التي تنتمي إلى فئة مثبطات &quot;mTOR&quot;). انظر قسم: &quot;تحذيرات واحتياطات&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ساكوبيتريل/ فالسارتان (لعلاج فشل القلب).</p><p dir="RTL">لا تتناول عقار أملوهوب إذا كنت تتناول حاليًا أو تناولت سابقًا ساكوبيتريل/ فالسارتان (انظر: &quot;لا تتناول عقار أملوهوب في الحالات الآتية&quot;)<em>.</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مُدِرات البول (أقراص الماء) مثل: فوروسيميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الخافضة لضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتاج طبيبك إلى ضبط جرعتك و/ أو اتخاذ إجراءات احتياطية أخرى:</p><p dir="RTL">إذا كنت تتناول أحد مناهضات مستقبلات الأنجيوتنسين-2 أو أليسكيرين (انظر أيضًا قسمي: &quot;لا تتناول عقار أملوهوب في الحالات الآتية&quot; و&quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إريثروميسين، كلاريثروميسين (مضادات حيوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم (بما في ذلك بدائل الملح)، مدرات البول المُوفرة للبوتاسيوم (مجموعة معينة من أقراص الماء مثل: سبيرونولاكتون، تريامتيريد أو أميلوريد) والأدوية الأخرى التي قد تزيد من مستوى البوتاسيوم في الدَّم، مثل ترايميثوبريم وكو-ترايموكسازول، التي تعرف أيضًا باسم ترايميثوبريم/ سلفاميثوكسازول والتي تُستخدم كمضادات للعدوى البكتيرية؛ سيكلوسبورين وتاكروليموس، وهما دواءان يُستخدمان لكبت الجهاز المناعي لمنع رفض الأعضاء المزروعة، وهيبارين، وهو دواء يُستخدم لتحسين سيولة الدَّم ومنع تكون جلطات دموية).</p><p dir="RTL">إذا كنت تتناول هذه الأدوية في الوقت نفسه، يجب مراقبة مستويات البوتاسيوم في الدم عن كثب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على الستيرويد المُخصصة لعلاج الالتهاب مثل: بريدنيزولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألوبيورينول (يُستخدم لخفض مستويات حمض اليوريك في الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بروكايناميد (يُستخدم لعلاج اضطرابات نظم القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تؤثر على تعدادات خلايا الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، إتراكونازول (يُستخدمان لعلاج العدوى الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير، إندينافير، نيلفينافير (تُستخدم لعلاج المرضى المصابين بعدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; دانتُرولين (يُستخدم للتسريب في حالة الإصابة باضطرابات شديدة في درجة حرارة الجسم [ارتفاع درجة الحرارة]).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فيلداجليبتن (يُستخدم لعلاج مرض السُّكَّرِي من النوع الثاني).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; راسيكادوتريل (يُستخدم لعلاج الإسهال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، ديلتِيازِيم (يُستخدمان لعلاج بعض أمراض القلب وارتفاع ضغط الدَّم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية. فقد تتأثر بعقار أملوهوب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج مرض السُّكَّرِي مثل الأدوية الخافضة لسكر الدم التي تُستخدم عن طريق الفم والأنسولين.</p><p dir="RTL">قد يُخفض عقار أملوهوب من مستوى السكر لديك بالدَّم. لذلك، يجب مراقبة مستويات السكر في الدم عن كثب أثناء تناوُل عقار أملوهوب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (يُستخدم لعلاج الأمراض النفسية).</p><p dir="RTL">يمكن لعقار أملوهوب أن يزيد من تركيز الليثيوم في الدَّم. لذلك، سيتوجب على طبيبك مراقبة مستويات الليثيوم الخاصة بك عن كثب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong>سيمفاستاتين (دواء خافض لمستوى الكوليسترول): يُزيد أملوديبين من الإتاحة (التَّعرض) الخاصة بسيمفاستاتين. سيتعين على طبيبك خفض جرعة سيمفاستاتين إذا كنت تتناول عقار أملوهوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا من ذلك)، فاسأل طبيبك قبل تناول عقار أملوهوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل عقار أملوهوب مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يجب على المرضى الذين يتناولون عقار أملوهوب عدم شرب عصير الجريب فروت أو تَناوُل الجريب فروت؛ حيث قد يُؤدي ذلك إلى ارتفاع مستويات المادة الفعَّالة أملوديبين بالدَّم، مما قد يتسبب في حدوث زيادة غير منضبطة في تأثير عقار أملوهوب الخافض لضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يتسبب تَناوُل الكحوليات أثناء تَناوُل عقار أملوهوب في حدوث دوخة ونعاس. اسأل طبيبك إذا كنت غير متأكد من كمية الكحوليات التي يُسمح لك بشربها أثناء تناول عقار أملوهوب؛ وذلك لأنَّ الأدوية الخافِضة لضَغْطِ الدَّم والكحوليات قد تزيد من تأثير بعضهم البعض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (<u>أو قد تكونين حاملًا</u>). كقاعدة، سيوصيكِ طبيبكِ بالتوقف عن تناوُل عقار أملوهوب قبل الحمل أَو بِمجرّد أَن تعلمي بِأنكِ حامل، وسيوصيك بِتناوُل دواء آخر. لا يُوصى بتناوُل عقار أملوهوب في المرحلة المبكرة من الحمل، ويجب عدم تناوُله بعد انقضاء الشهر الثالث من الحمل؛ حيث قد يُلحِق عقار أملوهوب بِجنينكِ ضررًا جسيمًا في هذه المرحلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ إبلاغ طبيبكِ فورًا إذا أصبحتِ حاملًا أثناء العلاج بعقار أملوهوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يتم الانتقال إلى علاج آخر مناسب قبل الحمل المُخطط له.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبكِ إذا كنتِ مرضعًا أو ترغبين في بدء ممارسة الرضاعة الطبيعية. لا يُوصى بتناوُل عقار أملوهوب من قبل الأمهات اللاتي يمارسن الرضاعة الطبيعية. قد يختار لكِ طبيبك علاجًا مختلفًا إذا كنتِ ترغبين في ممارسة الرضاعة الطبيعية، خاصةً إذا كان طفلكِ حديث الولادة أو مبتسرًا (وُلد قبل أوانه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناول أو استخدام أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التَّأثيرات في القدرة على القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن لعقار أملوهوب أن يضعف من قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">قد تشعر بتوعك، دوخة، تعب أو قد تعاني من صداع أثناء تناوُل عقار أملوهوب. تصل احتمالية تعرضك لهذه الأعراض إلى أقصى درجاتها عند بدء العلاج بعقار أملوهوب أو إذا قمت بزيادة الجرعة. في هذه الحالة، يجب ألا تمارس القيادة وألا تقم بتشغيل أي أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار أملوهوب على أزوروبين </strong><strong>(</strong><strong>E 122</strong><strong>)</strong></p><p>من الممكن أن يسبب أزوروبين (E 122) تفاعلات حساسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم فقط هذا الدَّواء حسب تعليمات طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تَناوُل الدواء </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تَناوَل هذا الدواء في الوقت نفسه من كل يوم، في أوقات تناول الوجبات أو بينها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولات الصلبة كاملة مع بعض السوائل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا تسحق الكبسولات الصلبة أو تمضغها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول هذا الدَّواء<sup> </sup>مع عصير الجريب فروت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة كبسولة صلبة واحدة بالتركيز الذي يصفه الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بزيادة الجرعة أو ضبطها حسب التأثير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة القصوى كبسولة صلبة واحدة بتركيز 10 مجم/ 10 مجم مرة واحدة يوميًّا.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>المرضى من كبار السن</u><u> </u></p><p dir="RTL">سيقوم طبيبك بخفض جرعتك الأولية وضبط العلاج ببطء. لا يُوصى بإعطاء عقار أملوهوب كبسولات صلبة للمرضى الكبار جدًّا في السن والضعاف.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><u>الاستخدام في الأطفال والمراهقين</u></p><p dir="RTL">لا يُوصى باستخدام عقار أملوهوب في الأطفال والمراهقين الأقل من 18 عامًا؛ نظرًا لعدم توافر بيانات كافية حول الأمان والفعالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك انطباع أن تأثير الدواء أقوى من اللازم أو أقل من اللازم، فتحدَّث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار أملوهوب</strong></p><p dir="RTL">إذا تناولت كمية كبيرة للغاية من الكبسولات، فقد ينخفض ضغط الدَّم لديك أو حتى يصبح منخفضًا بشكل خطير. قد تشعر بدوخة، دوار وضعف أو إغماء. إذا كان الانخفاض في ضغط الدَّم شديدًا بما يكفي، فقد يؤدي إلى حدوث صدمة. قد تشعر بأن جلدك أصبح باردًا ورطبًا وقد تفقد الوعي. استشر الطبيب أو اذهب إلى قسم الحوادث والطوارئ بأقرب مستشفى. لا تمارس القيادة بنفسك وأنت متوجهًا إلى المستشفى، بل اطلب من أي شخص آخر القيام بذلك أو اطلب سيارة الإسعاف. خذ معك عبوة الدواء حتى يعرف الطبيب ما الذي قمت بتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار أملوهوب</strong></p><p dir="RTL">إذا أغفلت تناوُل إحدى الجرعات، فتناوَل الجرعة التالية في الموعد التالي المُقرر. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول عقار أملوهوب</strong></p><p dir="RTL">لا توقف العلاج بشكل مفاجئ ولا تُغير الجرعة الموصوفة لك دون استشارة طبيبك المعالج؛ حيث قد يتفاقم مرضك بشكل مؤقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاتصل بطبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول عقار أملوهوب فورًا واتصل بطبيبك دون تأخير</strong> إذا لاحظت أيًّا من الآثار الجانبية الخطيرة التالية - فقد تحتاج إلى علاج طبي عاجل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين أو الحلق مما يتسبب في حدوث صعوبة في البلع أو التنفس، فضلًا عن الحكة وحالات الطفح الجلدي.</p><p dir="RTL">قد تكون هذه علامة على الإصابة بأحد تفاعلات فرط الحساسية الشديدة تجاه هذا العقار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة تشمل طفحًا جلديًّا، قرحًا في الفم، طفحًا جلديًّا مصحوبًا ببثور على الشفتين والعينين والفم، تفاقم أمراض جلدية موجودة مسبقًا، احمرارًا، حكة شديدة، ظهور بثور، تقشُّر الجلد وتورمه، التهاب الأغشية المخاطية (مثل: متلازمة ستيفنز جونسون، انحلال البشرة النخري التَّسَمُّمِيّ، احمرارًا متعدد الأشكال) أو تفاعلات حساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغ طبيبك فورًا إذا عانيت من الآتي</strong><strong>: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تسارع معدل ضربات القلب، عدم انتظام ضربات القلب أو قوتها (خفقان)، عدم انتظام أو بطء ضربات القلب، ألم أو ضيق في الصدر (ذبحة صدرية) أو أحداث خطيرة مثل النوبة القلبية أو السكتة الدماغية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس (صعوبة التَّنفُّس أو أزيز بالصدر) أو سعال.</p><p dir="RTL">هذه علامات محتملة للإصابة بمرض بالرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التعرض لكدمات بشكل أسهل، حدوث نزيف يستمر لفترة أطول من المعتاد، ظهور أي علامات للنزيف (على سبيل المثال: نزيف اللثة)، ظهور بقع أرجوانية على الجلد، زيادة القابلية للإصابة بالعدوى، التهاب الحلق والحمى، تعب، ضعف، دوخة أو شحوب الجلد.</p><p dir="RTL">هذه علامات مُحتملة على الإصابة بمرض بالدم أو النخاع العظمي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بالبطن قد يمتد إلى الظهر.</p><p dir="RTL">هذه علامات محتملة على الإصابة بالتهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمى، قشعريرة، إرهاق، فقدان الشهية، ألم بالبطن، غثيان، بول داكن، اصفرار الجلد أو العينين (يرقان).</p><p dir="RTL">هذه علامات مُحتملة على الإصابة بأمراض بالكبد مثل التهاب الكبد أو تلف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في معدل التخلص من البول، تورُّم، فقدان الشهية، غثيان، قيء، إرهاق، صعوبة التنفس، عدم انتظام النظم القلبي.</p><p dir="RTL">قد تكون هذه إحدى العلامات على الإصابة بمرض كلوي شديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المُحتمَلة الأخرى </strong></p><p dir="RTL"><strong>شائعة جدًّا</strong><strong>:</strong> قد تُؤثر على أكثر من مريض واحد من بين كل 10 مرضى يتم علاجهم</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورم (وذمة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong><strong>:</strong> قد تؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى يتم علاجهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نعاس (خاصةً عند بدء العلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خَفَقان (الإحساس بضربات القلب)، احمرار الجلد (هبات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم الكاحلين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع أو الشعور بالتعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">تصل احتمالية تعرضك لهذه الأعراض إلى أقصى الدرجات عند بدء العلاج باستخدام راميبريل هيكسال مع أملوديبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إغماء (غشى)، انخفاض ضغط الدَّم (انخفاض ضغط الدم بشكل غير معتاد)، خاصةً عند النهوض أو الوقوف بسرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية (بما في ذلك ازدواج الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سعال جاف، التهاب الجيوب الأنفية أو التهاب الشعب الهوائية، ضيق التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة أو الأمعاء، تغير معدل التبرز (بما في ذلك الإسهال والإمساك)، توعك بالبطن، اضطرابات بالجهاز الهضمي، شعور بالتوعك أو القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة و/ أو الأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب أو غير مصحوب بتهيُّج الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; آلام أو تقلصات عضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البوتاسيوم في الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>:</strong> قد تؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض يتم علاجهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تقلب الحالة المزاجية، مزاج مكتئب، قلق، تململ أو عصبية غير معتادة، اضطرابات في النوم (أَرَق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بالرؤية (بما في ذلك عدم وضوح الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طنين بالأذنين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عطس/ سيلان الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حكة، طفح جلدي مُعَمم، ظهور بقع أرجوانية على الجلد (فرفرية)، تغير لون الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في التخلص من البول، التبول بمعدل أكثر تكرارًا من المعتاد أثناء اليوم خاصةً ليلًا، تفاقم البيلة البروتينية الموجودة بالفعل (ارتفاع مستويات البروتين في البول بدرجة أكبر من المعتاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن أو فقدانه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الثديية لدى الرجال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران (دوار).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حكة وشعور غير معتاد بالجلد مثل تنميل، وخز، لسع، حرقة أو نخز في الجلد (اضطرابات بالإحساس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حساسية الجلد (تدنِّي الإحساس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان أو تغير في حاسة التَّذوق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف، صعوبة التنفس أو أزيز بالصدر، تفاقم الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الأمعاء، وذمة وعائية معوية مصحوبة بأعراض مثل ألم بالبطن، قيء وإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة، غثيان (التهاب المعدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرُّق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان أو انخفاض الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم الذراعين والساقين.</p><p dir="RTL">هذه علامات مُحتملة على حدوث تراكُم للسوائل بالجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات جنسية لدى الرجال، انخفاض الرغبة الجنسية لدى الرجال والسيدات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد بعض خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات) (يتم الكشف عنها من خلال اختبار الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قيم للدم تشير إلى وجود اضطرابات في وظائف الكبد، البنكرياس أو الكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية، مرض بالأوعية الدموية للقلب (إِقْفار عضلة القلب)، ضيق وألم في الصدر (ذبحة صدرية)، تسارع معدل ضربات القلب أو عدم انتظامه أو بطئه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين أو الحلق (انظر النصيحة الواردة في بداية قسم: 4).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قصور في وظائف الكُلى، بما في ذلك مرض كلوي شديد (فشل كلوي حاد) (انظر النصيحة الواردة في بداية قسم: 4).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong><strong>: </strong>قد تُؤثر على ما يصل إلى مريض واحد من بين كل 1000 مريض يتم علاجهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك أو شعور بالارتباك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالتَّوازن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احمرار اللسان وتورمه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تقشر شديد بالجلد أو تشققه، طفح جلدي بارز مصحوب بحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالأظافر (على سبيل المثال: فقدان أو انفصال الظفر من فِراش الظُّفُر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو كدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع على الجلد وبرودة الأطراف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العينين، شعور بحكة بهما أو تورمهما أو زيادة إفراز الدموع بهما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالسمع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم الحمراء، خلايا الدَّم البيضاء أو الصفائح الدَّموية، انخفاض شديد في قيمة الهيموجلوبين في اختبارات الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضيق الأوعية الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (ركود صفراوي)، تلف خلايا الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا</strong><strong>:</strong><strong> </strong>قد تؤثر على ما يصل إلى مريض واحد من بين كل 10000 مريض يتم علاجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحساسية تجاه أشعة الشمس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السكر في الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشد العضلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بالأعصاب قد يُسبب ضعفًا أو وخزًا أو تنميلًا بالعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تَكاثُر لِثَوِيّ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة (انظر النصيحة الواردة في بداية قسم: 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الإضافية التي تم الإبلاغ عنها</strong> (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">أبلغ طبيبك إذا أثرت أيٌّ من الآثار الجانبية المدرجة عليك بشكل ملحوظ أو استمرت لأكثر من بضعة أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التركيز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية بالفم مع وجود قرح صغيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في خلايا الدم بتعداد خلايا الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في مستويات الصوديوم بالدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون أصابع اليدين والقدمين عند الشعور بالبرد، الإحساس بوخز أو ألم عند الدفء (متلازمة رينود).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف القدرة على التفاعل أو التفاعل ببطء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بحرقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة الشم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع سميكة حمراء/ فضية اللون بالجلد (صدفية) أو طفح جلدي ذي مظهر فضي اللون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي على الأغشية المخاطية (طفح باطِن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قصور وظائف النخاع العظمي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدورة الدموية بالمخ بما في ذلك السكتة الدماغية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد بعض الأجسام المضادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بول مُركّز (داكن اللون)، غثيان أو قيء، تقلصات عضلية، ارتباك ونوبات تشنجية قد تكون ناجمة عن الإفراز غير المناسب للهرمون المضاد لإدرار البول. اتصل بطبيبك على الفور إذا حدثت هذه الأعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف، تصلب وضعية الجسم، وجه أشبه بالقناع، حركات بطيئة وجر القدمين، مشية غير متوازنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن يسبب أزوروبين (E 122) تفاعلات حساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا لاحظت أية آثار جانبية، يُرجى الاتصال بطبيبك أو الصيدلي الخاص بك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. عن طريق الإبلاغ عن الآثار الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية الخارجية وعبوة الشرائط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تستخدم هذا الدَّواء إذا لاحظت أية علامات واضحة تدل على عدم قابلية الاستخدام (مثل: تغيُّر اللون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص أبدًا من الأدوية عن طريق إلقائها في مياه الصرف (أي ليس في البالوعة أو المرحاض). اسأل الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. سيساعد ذلك على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي:</p><p dir="RTL">تحتوي كل كبسولة صلبة على 10 مجم راميبريل و 10 مجم أملوديبين (على هيئة بيسيلات الأملوديبين 13.9 مجم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><em>حشوة الكبسولة</em><em>:</em> كروسبوفيدون، هيبروميلوز، سليلوز دقيق التَّبلور، ثنائي بهينات الجليسيرول (هيئة دستور الأدوية الأوروبي).</p><p dir="RTL"><em>قاعدة الكبسولة وغطاء الكبسولة</em><em>:</em> أنديجو كارمين (E 132)، أزوروبين (E 122)، ثاني أكسيد التيتانيوم (E 171)، جيلاتين</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار أملوهوب عبارة عن كبسولات جيلاتينة صلبة غير مميزة بعلامة، ذاتية الغلق من نوعية كوني-سناب مقاس 0 قاعدتها غير شفافة حمراء/ بنية اللون وغطاؤها غير شفاف أحمر/ بني اللون. محشوة بمسحوق حبيبي أبيض اللون أو يميل إلى الأبيض، عديم الرائحة أو شبه عديم الرائحة وليس به أية شوائب ميكانيكية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر عقار أملوهوب في عبوات تحتوي على 10 أو 20 أو 30 أو 50 أو 90 أو 100 كبسولة صلبة في عبوات شرائط بعبوة كرتونية.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p dir="RTL">هيكسال أيه جي،</p><p dir="RTL">25 شارع إندستري</p><p dir="RTL">83607&nbsp; هولزكيرشن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong><strong>:</strong></p><p dir="RTL">شركة ليك للصناعات الدَّوائية شركة مساهمة</p><p dir="RTL">57 فيروفسكوفا</p><p dir="RTL">1526 ليوبليانا</p><p dir="RTL">سلوفينيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	06/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlohope 5 mg/5 mg hard capsules 
Amlohope 10 mg/5 mg hard capsules 
Amlohope 5 mg/10 mg hard capsules 
Amlohope 10 mg/10 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlohope5 mg/5 mg
Each capsule contains 5 mg ramipril and 5 mg amlodipine (as amlodipine besilate 6.95 mg). Excipients with known effect: 0.048 mg Allura Red (E129) per hard capsule
Amlohope10 mg/5 mg
Each hard capsule contains 10 mg ramipril and 5 mg amlodipine (as amlodipine besilate 6.95 mg). Excipients with known effect: 0.038 mg Allura Red (E129) per hard capsule
Amlohope5 mg/10 mg
Each capsule contains 5 mg ramipril and 10 mg amlodipine (as amlodipine besilate 13.9 mg). Excipients with known effect: 0.25 mg Azorubine (E122) per hard capsule
Amlohope10 mg/10 mg
Each hard capsule contains 10 mg ramipril and 10 mg amlodipine (as amlodipine besilate 13.9 mg). Excipients with known effect: 0.64 mg Azorubine (E122) per hard capsule
For the full list of excipients, see Section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule

Amlohope5 mg/5 mg
Unmarked, self-closing Coni-Snap size 3 hard gelatin capsules with opaque amethyst-colored capsule bottom and opaque amethyst-colored capsule cap filled with white or almost white, odorless or almost odorless granulate powder without mechanical contamination.

Amlohope10 mg/5 mg
Unmarked, self-closing Coni-Snap size 0 hard gelatin capsules with opaque flesh-colored capsule bottom and opaque amethyst-colored capsule cap filled with white or almost white, odorless or almost odorless granulate powder without mechanical contamination.

Amlohope5 mg/10 mg
Unmarked, self-closing Coni-Snap size 0 hard gelatin capsules with opaque flesh-colored capsule bottom and opaque red-brown-colored capsule cap filled with white or almost white, odorless or almost odorless granulate powder without mechanical contamination.

Amlohope10 mg/10 mg
 
Unmarked, self-closing Coni-Snap size 0 hard gelatin capsules with opaque red-brown-colored capsule bottom and opaque red-brown-colored capsule cap filled with white or almost white, odorless or almost odorless granulate powder without mechanical contamination.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amlohope is indicated as substitution therapy for the treatment of hypertension in patients who are sufficiently adjusted when both active substances are administered as single tablets at the same strength as in the combination preparation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Posology</p><p>Amlohope is indicated as substitution therapy for the treatment of hypertension in patients whose blood pressure is sufficiently managed by concomitant administration of the single products at the same strength as in the combination preparation.</p><p>&nbsp;</p><p>The recommended daily dose is 1 hard capsule of the prescribed strength. Taking the combination product is not suitable for initial therapy.</p><p>If dose adjustment is necessary, this should only be done via the single agents. After dose adjustment, the change to the appropriate combination preparation of Amlohope is possible.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Diuretic treated patients</em></p><p>Caution should be exercised in patients treated with diuretics, since fluid and/or salt deficiency can occur in these patients. Renal function and serum potassium should be monitored regularly.</p><p>&nbsp;</p><p><em>Impaired hepatic function</em></p><p>Treatment with <em>ramipril </em>should only be initiated under strict medical supervision in patients with impaired hepatic function. The maximum daily dose is 2.5 mg ramipril.</p><p>&nbsp;</p><p>&nbsp;</p><p>In patients with impaired hepatic function, the half-life of <em>amlodipine </em>may be prolonged. To date, there are no specific dose recommendations for <em>amlodipine </em>for this patient group, therefore particular caution is required when taking the medicinal product (see section 4.4).</p><p>&nbsp;</p><p>In general, treatment with Amlohope in the case of impaired hepatic function is not recommended, as the maximum daily dose for this patient group is exceeded with this drug.</p><p>&nbsp;</p><p><em>Impaired renal function</em></p><p>In order to determine the optimal initial and maintenance dose in patients with impaired renal function, an individual dose adjustment should be done by separate adjustment of the ramipril and amlodipine components (details can be found in the Summary of Product Characteristics for the respective individual components).</p><p>&nbsp;</p><p>The daily dose of <em>ramipril </em>in patients with renal impairment should be determined based on creatinine clearance.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If creatinine clearance is &ge; 60 ml/min, no adjustment of the initial dose is necessary; the maximal daily</p><p>dose is 10 mg.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; With a creatinine clearance of &lt; 60 ml/min and in hypertensive patients on hemodialysis, Amlohopeis recommended only in patients who were adjusted to 2.5 mg or 5 mg ramipril as the optimal maintenance dose. For hemodialysis patients, the medicinal product should be administered a few hours after completing &nbsp;hemodialysis.</p><p>&nbsp;</p><p>No dose adjustment of <em>amlodipine </em>is necessary in the case of patients with impaired renal function.</p><p>&nbsp;</p><p>Amlodipine is not dialyzable. In patients requiring dialysis, <em>amlodipine </em>should be used with caution (see section 4.4).</p><p>&nbsp;</p><p>Regular monitoring of renal function and serum potassium is necessary during treatment with Amlohope. If renal function deteriorates, it is recommended to discontinue treatment with Amlohope and instead to administer the individual components at appropriately adjusted dosages.</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>The initial dose of ramipril should be lower and subsequent dose adjustment should be more gradual, as the chance of side effects is higher.</p><p>&nbsp;</p><p>Administration of Amlohopeis not recommended in very old and frail patients.</p><p>&nbsp;</p><p>The usual dosages of amlodipine may be administered to elderly patients. However, caution is advised when increasing the dose (see section 5.2).</p><p>&nbsp;</p><p><em>Pediatric population</em></p><p>The use of Amlohopein children and adolescents under 18 years of age is not recommended, as there is insufficient data on safety and efficacy. The data currently available for ramipril are described in sections 4.8, 5.1 and 5.2. However, no specific dosage recommendations can be given.</p><p>&nbsp;</p><p>Method of administration</p><p>Amlohope should be taken once daily at the same time of day or independently of meals. The hard capsule must not be chewed or crushed. The hard capsules should be taken with sufficient fluids (e.g. water). The hard capsules should not be taken with grapefruit juice.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For ramipril
•	History of angioedema (hereditary, idiopathic, or due to previous angioedema with ACE inhibitors or
angiotensin II receptor antagonists [AIIRAs]).
•	Concomitant use of sacubitril/valsartan therapy. Treatment with Amlohope may be started 36 hours after the last dose of sacubitril/valsartan (see also sections 4.4 and 4.5)
•	Extracorporeal treatments leading to blood coming into contact with negatively charged surfaces (see section 4.5)
•	Significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney
•	2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6)
•	In hypotensive or hemodynamically unstable patients.

The concomitant use of Amlohope with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).

For amlodipine
•	Severe hypotension
•	Shock (including cardiogenic shock)
•	Obstruction of the left ventricular discharge tract (e.g. higher grade aortic stenosis)
•	Hemodynamically unstable heart failure after acute myocardial infarction
For Amlohope
 
•	Hypersensitivity to the amlodipine, dihydropyridine derivatives, ramipril or other ACE inhibitors (ACE = angiotensin-converting enzyme) or to any of the excipients listed in section 6.1.

Additionally for Amlohope5 mg/10 mg/- 10 mg/10 mg
•	Hypersensitivity to azorubine

Additionally for Amlohope5 mg/5 mg/- 10 mg/5 mg
•	Hypersensitivity to Allura Red

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; For ramipril</p><p><u>Special populations Pregnancy</u></p><p>Treatment with ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti- hypertensive treatments which have an established safety profile for use in pregnancy. If pregnancy is confirmed, treatment with ACE inhibitors should be discontinued immediately and, where required, alternative treatment should be initiated (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><u>Patients at high risk of hypotension</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <em>Patients with strongly activated renin-angiotensin-aldosterone system</em></p><p>There is a risk of an acute pronounced fall in blood pressure and deterioration of renal function due to ACE inhibition. This applies in particular if an ACE inhibitor is administered for the first time or initially with a diuretic or at the first dose increase.</p><p>Significant activation of the renin-angiotensin-aldosterone system is to be expected and medical supervision including blood pressure monitoring is necessary in the following patients for example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with severe hypertension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with decompensated heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with hemodynamically relevant left ventricular inflow or outflow impediment (e.g. aortic or mitral valve stenosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with unilateral renal artery stenosis with a second functional kidney</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with manifest or latent fluid or salt depletion (including patients on diuretics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with liver cirrhosis and/or ascites</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients undergoing major surgery or during anesthesia with agents that can cause hypotension Generally, it is recommended to correct dehydration, hypovolemia or salt depletion before initiating treatment (in patients with heart failure, however, such corrective action must be carefully weighed up against the risk of volume overload).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <em>Transient or persistent heart failure post myocardial infarction</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <em>Patients at risk of cardiac or cerebral ischemia in the case of acute hypotension</em></p><p>The patient must be monitored carefully during the initial phase of treatment.</p><p>&nbsp;</p><p><u>Elderly patients </u>See section 4.2</p><p>&nbsp;</p><p><u>Surgery</u></p><p>It is recommended that treatment with ACE inhibitors such as ramipril should be discontinued where possible one day before surgery.</p><p>&nbsp;</p><p><u>Monitoring of renal function</u></p><p>Renal function should be monitored before and during treatment and any corresponding dose adjustment should be performed during the initial weeks of treatment in particular. Particularly careful monitoring is required in patients with renal impairment (see section 4.2). There is a risk of impairment of renal function, particularly in patients with congestive heart failure or after a kidney transplant.</p><p>&nbsp;</p><p><u>Hypersensitivity/angioedema</u></p><p>Angioedema has been reported in patients treated with ACE inhibitors including ramipril (see section 4.8).</p><p>&nbsp;</p><p>Concomitant use of ACE inhibitors and sacubitril/valsartan is contraindicated due to the increased risk of angioedema. Treatment with sacubitril/valsartan may be started 36 hours after the last dose of Ramipril HEXAL plus Amlodipine. Treatment with Amlohopemay be started 36 hours after the last dose of sacubitril/valsartan (see also sections 4.3 and 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant administration of ACE inhibitors and racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and vildagliptin can lead to an increased risk of angioedema (e.g. swelling of the respiratory tract or tongue with or without difficulty breathing) (see section 4.5). Caution is advised when treatment with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and vildagliptin is started in patients who already take ACE inhibitors.</p><p>&nbsp;</p><p>&nbsp;</p><p>In the case of angioedema, treatment must be discontinued.</p><p>Emergency therapy should be initiated immediately. The patient should be kept under observation for at least 12-24 hours and only discharged after complete resolution of the symptoms.</p><p>&nbsp;</p><p>Intestinal angioedema has been reported in patients treated with ACE inhibitors including ramipril (see section 4.8). These patients presented with abdominal pain (with or without nausea or vomiting).</p><p>&nbsp;</p><p><u>Anaphylactic reactions during desensitization</u></p><p>The likelihood and severity of anaphylactic and anaphylactoid reactions to insect venom and other allergens are increased under ACE inhibition. Temporary discontinuation of ramipril should be considered prior to desensitization.</p><p>&nbsp;</p><p><u>Monitoring of electrolytes: Hyperkalemia</u></p><p>Hyperkalemia has been observed in some patients treated with ACE inhibitors including ramipril. ACE inhibitors can trigger hyperkalemia because they inhibit the release of aldosterone. The effect is generally not significant in patients with normal renal function. However, hyperkalemia can occur in patients with renal impairment, aged over 70 years, with uncontrolled diabetes mellitus, states such as dehydration, acute cardiac decompensation, metabolic acidosis, or in patients taking potassium substitutes (including salt substitutes), potassium-sparing diuretics or other active substances that increase plasma potassium levels (e.g. heparin, trimethoprim, co-trimoxazole, also known as trimethoprim/sulfamethoxazole and especially aldosterone antagonists or angiotensin receptor inhibitors). If concomitant use of the above-mentioned substances is deemed appropriate, regular monitoring of serum potassium is recommended. Potassium- sparing diuretics and angiotensin receptor inhibitors should be used with caution in patients receiving ACE inhibitors and potassium level and renal function should be monitored (see section 4.5).</p><p>&nbsp;</p><p><u>Monitoring of electrolytes: Hyponatremia</u></p><p>Syndrome of Inappropriate Anti-diuretic Hormone Secretion (SIADH) and subsequent hyponatremia has been observed in some patients treated with ramipril. It is recommended that serum sodium levels be monitored regularly in the elderly and in other patients at risk of hyponatremia.</p><p>&nbsp;</p><p><u>Neutropenia/agranulocytosis</u></p><p>In rare cases, neutropenia/agranulocytosis, as well as thrombocytopenia and anemia, have been observed and bone marrow depression has also been reported. Monitoring of leukocyte counts is recommended to recognize potential leukopenia. More frequent monitoring is advisable in the initial phase of treatment and in patients with impaired renal function, in patients with concomitant collagenosis (e.g. lupus erythematosus or scleroderma) and all patients who are treated concomitantly with other drugs that can cause blood count changes (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><u>Ethnic differences</u></p><p>ACE inhibitors cause angioedema more frequently in black patients than in non-black patients.</p><p>&nbsp;</p><p>As with other ACE inhibitors, ramipril may be less effective at lowering blood pressure in black patients than in non-black patients, possibly because of a higher prevalence of hypertension with low renin level in the black hypertensive population.</p><p>&nbsp;</p><p><u>Cough</u></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&nbsp;</p><p><u>Patients undergoing diuretic therapy </u>See section 4.2</p><p>&nbsp;</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalemia and decreased renal function (including acute renal failure). Dual blockade of the RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>For amlodipine</p><p>The safety and efficacy of amlodipine in a hypertensive crisis has not yet been confirmed. <u>Special populations</u></p><p><u>Patients with heart failure</u></p><p>Caution is advised when treating patients with heart failure. In a placebo-controlled long-term study in patients with severe heart failure (NYHA classes III and IV), pulmonary edema was reported more frequently on amlodipine than on placebo (see section 5.1).</p><p>Calcium channel blockers, including amlodipine, should be used with caution in patients with decompensated heart failure, as they can increase the risk of future cardiovascular events and the risk of mortality.</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>The half-life of amlodipine is prolonged in patients with impaired hepatic function and AUC values are higher; so far there are no dosage recommendations. Amlodipine should therefore be started within the lower dosage range and should be administered with caution both at the start of treatment and with a dose increase. In patients with severely impaired liver function, slow dose titration and close monitoring may be necessary.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>In elderly patients, the dosage should only be increased with caution (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>Amlodipine can be used in this patient group at the usual dose. There is no correlation between the degree of renal impairment and changes in amlodipine plasma levels. Amlodipine is not dialyzable.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Special warnings relating to the other components</u></p><p>Amlohope5 mg/5 mg and 10 mg/5 mg hard capsules contain the colorant Allura Red (E129) which can cause allergic reactions.</p><p><br />Amlohope5 mg/10 mg and 10 mg/10 mg hard capsules contain the colorant Azorubine (E122) which can cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>For ramipril</strong></p><p><u>Contraindicated&nbsp; combinations</u></p><p>Extracorporeal treatments in which blood comes into contact with negatively charged surfaces, such as dialysis or hemofiltration with certain high-flux membranes (e.g. polyacrylic nitrile membranes) and low- density lipoprotein apheresis with dextran sulfate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of anti-hypertensive agent.</p><p>&nbsp;</p><p>Medicines that increase the risk of angioedema: Concomitant use of ACE inhibitors and sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Precautionary measures for use</u></p><p><em>Potassium-sparing diuretics, potassium substitutes or potassium-containing salt substitutes and other active substances that increase serum potassium (including angiotensin II antagonists, tacrolimus, cyclosporine, heparin): </em>Hyperkalemia may occur, therefore serum potassium must be closely monitored.</p><p>&nbsp;</p><p>Although serum potassium levels usually remain within the normal range, hyperkalemia may occur in some patients treated with ramipril. Potassium-sparing diuretics (e.g. spironolactone, triamterene, or amiloride), potassium supplements or potassium-containing salt supplements may cause a significant increase in serum potassium. Caution is also advised if ramipril is administered together with other agents that increase serum potassium, such as trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), because trimethoprim is known to act like a potassium-sparing diuretic such as amiloride. An increased incidence of hyperkalemia in patients who took ACE inhibitors and trimethoprim or trimethoprim in a fixed-dose combination with sulfamethoxazole (co-trimoxazole) was observed, therefore the combination of ramipril with the aforementioned drugs is not recommended. If concomitant use is indicated, it must be carried out with caution and with regular monitoring of the serum potassium (see section 4.4).</p><p><em>Cyclosporine</em></p><p>Hyperkalemia can occur with concomitant use of ACE inhibitors and cyclosporine. Monitoring of serum potassium is recommended.</p><p>&nbsp;</p><p><em>Heparin</em></p><p>Hyperkalemia can occur with concomitant use of ACE inhibitors and heparin. Monitoring of serum potassium is recommended.</p><p><em>Antihypertensives (e.g. diuretics) and other active substances that lower the blood pressure (e.g. nitrates, tricyclic antidepressants, anesthetics, acute alcohol intake, baclofen, alfuzosin, doxazosin, prazosin, tamsulosin, terazosin): </em>An increase in the risk of a drop in blood pressure is to be expected (see section 4.2 on diuretics).</p><p>&nbsp;</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with ACE inhibitors, angiotensin II receptor antagonists, or aliskiren:</em></p><p>Clinical trial data has shown that the dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalemia and decreased renal function (including acute renal failure) compared to the use of a single agent that acts on the RAAS (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><em>Vasopressor sympathomimetics and other active substances (e.g. isoproterenol, dobutamine, dopamine, epinephrine), which may weaken the antihypertensive effect of ramipril: </em>Regular blood pressure monitoring is recommended.</p><p>&nbsp;</p><p><em>Allopurinol, immunosuppressants, corticosteroids, procainamide, cytostatics and other active substances that can alter blood counts: </em>Increased probability of hematological reactions (see section 4.4).</p><p>&nbsp;</p><p><em>Lithium salts: </em>Excretion of lithium may be reduced by ACE inhibitors and therefore lithium toxicity may be increased. Regular monitoring of lithium levels is necessary.</p><p>&nbsp;</p><p><em>Anti-diabetic agents including insulin: </em>Hypoglycemia may occur. Regular monitoring of blood glucose levels is recommended.</p><p>&nbsp;</p><p><em>Non-steroidal anti-inflammatory drugs and acetylsalicylic acid: </em>Reduction of the anti-hypertensive effect of ramipril is to be expected. Furthermore, concomitant treatment of ACE inhibitors and NSAIDs may lead to an increased risk of deterioration of renal function and to an increase in serum potassium levels.</p><p>&nbsp;</p><p><em>Medicines that increase the risk of angioedema</em></p><p>Concomitant use of ACE inhibitors with NEP inhibitors (such as racecadotril), mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and DPP-IV inhibitors (vildagliptin) can lead to an increased risk of angioedema Caution is advisable at the start of treatment (see section 4.4).</p><p>&nbsp;</p><p><strong>For amlodipine</strong></p><p><strong>&nbsp;</strong></p><p><u>Influence of other medicines on amlodipine</u></p><p><em>CYP3A4 inhibitors:</em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antimycotics, macrolides such as erythromycin or clarithromycin, verapamil or diltiazem) can lead to a significant increase in amlodipine exposure. The clinical consequences of the altered pharmacokinetics can be more pronounced in elderly patients. Therefore, clinical monitoring and dose adjustment can be necessary.</p><p>Clarithromycin is an inhibitor of CYP3A4. There is an increased risk of hypotension in patients receiving clarithromycin together with amlodipine. Close monitoring of patients is recommended with concomitant administration of clarithromycin and amlodipine.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>CYP3A4 inducers:</em></p><p>Concomitant use of known CYP3A4 inducers may lead to different plasma levels of amlodipine. Thus, blood pressure should be monitored and dose regulation should be considered, both during as well as after concomitant administration of strong CYP3A4 inducers in particular (e.g. rifampicin, St. John&rsquo;s wort [Hypericum &nbsp;perforatum]).</p><p>&nbsp;</p><p><em>Grapefruit and grapefruit juice:</em></p><p>Concomitant use of amlodipine with grapefruit or grapefruit juice is not recommended because the bioavailability of amlodipine can be increased in some patients as a result. This would lead to increased blood pressure reduction.</p><p>&nbsp;</p><p><em>Dantrolene (infusion):</em></p><p>In animals, lethal ventricular fibrillation and circulatory collapse in connection with hyperkalemia were observed after administration of verapamil and intravenous dantrolene. Due to the risk of hyperkalemia, it is recommended to avoid concomitant administration of calcium blockers such as amlodipine in patients susceptible to hyperthermia or being treated due to malignant hyperthermia.</p><p><u>Influence of amlodipine on other medicines</u></p><p>Medicines with antihypertensive effect: The blood pressure lowering effect of amlodipine can intensify the blood pressure lowering effect of other antihypertensives.</p><p>&nbsp;</p><p><em>Tacrolimus:</em></p><p>With concomitant administration of amlodipine, there is a risk of increased tacrolimus levels in the blood. In order to avoid toxicity from tacrolimus, patients treated with the drug must monitor tacrolimus levels in the blood and adjust the dose if necessary.</p><p>&nbsp;</p><p><em>Cyclosporine:</em></p><p>No studies were conducted to record drug interactions with cyclosporine and amlodipine in healthy subjects or other patient groups. One exception is patients who have undergone kidney transplantation, where variable increases in trough level concentrations (average 0% to 40%) of cyclosporine were observed. In patients who have undergone kidney transplantation, monitoring of cyclosporine levels should be considered and, if necessary, the cyclosporine dose reduced.</p><p>&nbsp;</p><p><em>Simvastatin:</em></p><p>Simultaneous multiple administration of 10 mg amlodipine with 80 mg simvastatin led to a 77% increase in simvastatin exposure compared to administration of simvastatin alone. In patients receiving amlodipine, the dose of simvastatin should be limited to 20 mg daily.</p><p>&nbsp;</p><p><em>Atorvastatin, digoxin, or warfarin:</em></p><p>In clinical interaction studies, amlodipine showed no effect on the pharmacokinetics of atorvastatin, digoxin or warfarin.</p><p>&nbsp;</p><p><em>Mammalian target of rapamycin (mTOR) inhibitors</em></p><p>mTOR inhibitors such as sirolimus, temsirolimus and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use with mTOR inhibitors, amlodipine can increase the effect of the mTOR inhibitor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>For ramipril</strong></p><p>&nbsp;<!--[if mso & !supportInlineShapes & supportFields]><span
style='letter-spacing:-2.45pt'><span style='mso-element:field-begin;mso-field-lock:
yes'></span><span style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='width:464.15pt;
 height:26.85pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".42pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:1.4pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt;line-height:106%'><span
    style='mso-font-width:105%'>ACE<span style='letter-spacing:-.45pt'> </span>inhibitors<span
    style='letter-spacing:-.5pt'> </span>are<span style='letter-spacing:-.5pt'>
    </span>not<span style='letter-spacing:-.5pt'> </span>recommended<span
    style='letter-spacing:-.5pt'> </span>in<span style='letter-spacing:-.5pt'> </span>the<span
    style='letter-spacing:-.5pt'> </span>first<span style='letter-spacing:-.5pt'>
    </span>trimester<span style='letter-spacing:-.5pt'> </span>of<span
    style='letter-spacing:-.5pt'> </span>pregnancy<span style='letter-spacing:
    -.45pt'> </span>(see<span style='letter-spacing:-.5pt'> </span>section<span
    style='letter-spacing:-.45pt'> </span>4.4).<span style='letter-spacing:
    -.5pt'> </span>The<span style='letter-spacing:-.5pt'> </span>use<span
    style='letter-spacing:-.4pt'> </span>of<span style='letter-spacing:-.5pt'> </span>ACE
    inhibitors<span style='letter-spacing:-.55pt'> </span>in<span
    style='letter-spacing:-.55pt'> </span>the<span style='letter-spacing:-.5pt'>
    </span>second<span style='letter-spacing:-.55pt'> </span>and<span
    style='letter-spacing:-.55pt'> </span>third<span style='letter-spacing:
    -.55pt'> </span>trimester<span style='letter-spacing:-.55pt'> </span>of<span
    style='letter-spacing:-.55pt'> </span>pregnancy<span style='letter-spacing:
    -.5pt'> </span>is<span style='letter-spacing:-.55pt'> </span>contraindicated<span
    style='letter-spacing:-.55pt'> </span>(see<span style='letter-spacing:-.4pt'>
    </span>sections<span style='letter-spacing:-.55pt'> </span>4.3<span
    style='letter-spacing:-.55pt'> </span>and<span style='letter-spacing:-.5pt'>
    </span>4.4).</span><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="623" height="40" alt="Text Box: ACE inhibitors are not recommended in the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors in the second and third trimester of pregnancy is contraindicated (see sections 4.3 and 4.4)." src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='letter-spacing:-2.45pt'><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:464.15pt;height:26.85pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy is inconclusive; however, a small increase in risk cannot be excluded. Unless continuing ACE inhibitor therapy is considered essential, patients planning pregnancy should be switched to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. If pregnancy is confirmed, treatment with ACE inhibitors should be discontinued immediately and, where required, alternative treatment should be initiated.</p><p>&nbsp;</p><p>ACE inhibitor therapy exposure during the second and third trimesters is known to have fetotoxic effects (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxic effects (renal failure, hypotension, hyperkalemia) (see also section 5.3). In the event of exposure to ACE inhibitors from the second trimester of the pregnancy onwards, ultrasound examinations of renal function and the skull are recommended.</p><p>&nbsp;</p><p>Infants whose mothers have taken ACE inhibitors should be checked frequently for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>For amlodipine</p><p>The safety of amlodipine in pregnant women has not yet been confirmed.</p><p>&nbsp;</p><p>In animal experimental studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p>&nbsp;</p><p>Use during pregnancy is only recommended if no safer treatment alternatives are available and the disease represents a higher risk for mother and fetus.</p><p>&nbsp;</p><p>Breastfeeding <u>For ramipril</u></p><p>Because insufficient information is available regarding the use of ramipril during breastfeeding, ramipril is not recommended. An alternative treatment with a more suitable safety profile is preferable during breastfeeding, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p><p>For amlodipine</p><p>Amlodipine is excreted in human breast milk. The proportion of the maternal dose transferred to the infant is estimated at an interquartile range of 3 to 7%, with a maximum of 15%. It is not known whether amlodipine has effects on infants.</p><p>&nbsp;</p><p>In the decision to either continue/discontinue treatment with amlodipine, the benefit of breastfeeding for the child and the benefits of treatment with amlodipine for the mother must be taken into consideration.</p><p>&nbsp;</p><p>Fertility</p><p><strong>&nbsp;</strong></p><p><strong>For amlodipine</strong></p><p><strong>&nbsp;</strong></p><p>Reversible biochemical changes were observed in the heads of spermatozoa in some patients treated with calcium blockers. The clinical data regarding a possible influence of amlodipine on fertility is still insufficient. In a study in rats, there were negative effects on the fertility of male animals (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some adverse effects (e.g. dizziness, headache, fatigue or nausea) may impair the ability to concentrate and react in the patient and thus represent a risk in situations where these skills are of particular importance (e.g. driving or operating machines). This is particularly the case at the start of treatment or when changing over from other preparations. Driving a vehicle or operating machines is inadvisable for several hours after the first dose or subsequent dose increases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p><strong>&nbsp;</strong></p><p><u>Ramipril</u></p><p>&nbsp;</p><p>The most frequently reported adverse effects in treatment with ramipril are hyperkalemia, headache, dizziness, hypotension, orthostatic hypotension, syncope, dry cough, bronchitis, sinusitis, dyspnea, gastrointestinal inflammation, digestive disorders, digestive complaints, dyspepsia, diarrhea, nausea, vomiting, skin rash especially maculopapular, muscle cramps, myalgia, pain in the chest, fatigue.</p><p>Serious side effects include agranulocytosis, pancytopenia, hemolytic anemia, myocardial infarction, angioedema, vasculitis, bronchospasm, acute pancreatitis, liver failure, acute renal failure, hepatitis, exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. <u>Amlodipine</u></p><p>&nbsp;</p><p>The most frequently reported side effects during treatment with amlodipine are somnolence, dizziness, headache, palpitations, skin redness with warmth, abdominal pain, nausea, ankle swelling, edema, and fatigue.</p><p>&nbsp;</p><p>Serious adverse effects are leukopenia, thrombocytopenia, myocardial infarction, atrial fibrillation, ventricular tachycardia, vasculitis, acute pancreatitis, hepatitis, angioedema, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis and Steven-Johnson syndrome.</p><p>&nbsp;</p><p>The following frequency categories are used for side effects occurring during treatment with the individual active substances:</p><p>&nbsp;</p><p>Very common (&sup3; 1/10) Common (&sup3; 1/100 to &lt; 1/10)</p><p>Uncommon (&sup3; 1/1,000 to &lt; 1/100) Rare (&sup3; 1/10,000 to &lt; 1/1,000) Very rare (&lt; 1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Ramipril</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood</p><p>and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Decrease in leukocyte count (including neutropenia/agranulocytosis), Decrease in erythrocyte count, decreased</p><p>hemoglobin values, decrease in platelet count</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leucopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Bone marrow failure, pancytopenia, Hemolytic anemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaphylactic or anaphylactoid reactions, Increase in antinuclear antibodies</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Syndrome of inadequate antidiuretic</p><p>hormone secretion (SIADH)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Increase in serum potassium concentration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, reduced appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in serum sodium concentration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Depressive mood, anxiety, Nervousness, restlessness, sleep disorders</p><p>including somnolence</p></td><td style="vertical-align:top"><p>Mood changes (including anxiety), insomnia, depression</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Confusional states</p></td><td style="vertical-align:top"><p>Confusion</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Attention disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td><td style="vertical-align:top"><p>Headache, dizziness, somnolence</p><p>(especially at the start of treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo, paresthesia,</p></td><td style="vertical-align:top"><p>Tremor, dysgeusia, syncope,</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Ramipril</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ageusia,dysgeusia</p></td><td style="vertical-align:top"><p>hypesthesia, Paresthesia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Tremor, balance disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased muscle tone (hypertension), Peripheral neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cerebral ischemia including ischemic</p><p>stroke and transient ischemic attacks, impairment of psychomotor skills, feeling of burning, parosmia</p></td><td style="vertical-align:top"><p>Extrapyramidal&nbsp; disease</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision disorders (including diplopia)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vision disorders, including blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear</p><p>and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hearing impaired, tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myocardial ischemia, including angina pectoris or myocardial infarction, tachycardia, arrhythmia, palpitations, peripheral edema</p></td><td style="vertical-align:top"><p>arrhythmia (including bradycardia,</p><p>ventricular tachycardia and atrial fibrillation)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial&nbsp; infarction</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, orthostatic hypotension,</p><p>Syncope</p></td><td style="vertical-align:top"><p>Skin redness with feeling of warmth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vascular stenosis, hypoperfusion,&nbsp; vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s&nbsp; phenomenon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry cough, bronchitis, Sinusitis, dyspnea</p></td><td style="vertical-align:top"><p>Dyspnea</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Bronchospasm, including deterioration</p><p>of bronchial asthma, blocked nose</p></td><td style="vertical-align:top"><p>Cough, rhinitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Inflammation of the gastrointestinal tract, digestive disorders, digestive complaints,</p><p>dyspepsia, diarrhea, nausea, vomiting</p></td><td style="vertical-align:top"><p>Nausea, abdominal pain, dyspepsia,</p><p>altered bowel movements (including diarrhea and constipation)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis (deaths were reported in rare exceptions in connection with ACE inhibitors), increase in</p></td><td style="vertical-align:top"><p>vomiting, dry mouth</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Ramipril</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pancreatic enzymes, angioedema of the small intestine,</p><p>Upper abdominal pain incl. Gastritis, constipation, dry mouth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Glossitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Aphthous stomatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Hepatobiliary&nbsp; disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Increase in liver enzymes and/or</p><p>conjugated bilirubin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cholestatic jaundice, hepatocellular&nbsp; damage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice*, hepatitis*, increased liver enzyme values*</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Acute liver failure, cholestatic</p><p>or cytolytic hepatitis (in rare exceptional cases with fatal outcome)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash in particular maculopapular</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema; in rare exceptional cases</p><p>the airway obstruction due to angioedema can be fatal, pruritus,</p><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>alopecia, purpura, skin discoloration,</p><p>Hyperhidrosis, pruritus, rash, exanthema, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis, urticaria, onycholysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Photosensitivity</p></td><td style="vertical-align:top"><p>Angioedema, erythema multiforme,</p><p>exfoliative dermatitis,</p><p>Stevens-Johnson</p><p>syndrome, Quincke&rsquo;s edema, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens-</p><p>Johnson syndrome, erythema multiforme,</p><p>pemphigoid, deterioration of psoriasis,</p><p>psoriasiform dermatitis, pemphigoid</p><p>or lichenoid exanthema or enanthema, alopecia</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle spasms, myalgia</p></td><td style="vertical-align:top"><p>Ankle swelling, muscle cramps</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>arthralgia, myalgia, back pain</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Ramipril</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Renal impairment including acute</p><p>renal failure, increased urine excretion,</p><p>Deterioration of pre-existing proteinuria, increase in serum urea,</p><p>Increase in serum creatinine</p></td><td style="vertical-align:top"><p>micturition disorders, nocturia,</p><p>increased urination</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Transient erectile impotence, decreased libido</p></td><td style="vertical-align:top"><p>Impotence,&nbsp; gynecomastia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Gynecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Edema</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Chest pain, fatigue</p></td><td style="vertical-align:top"><p>Fatigue, asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Chest pain, pain, Malaise</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight gain, Weight loss</p></td></tr></tbody></table><p>&nbsp;</p><p>* usually associated with cholestasis <u>For ramipril</u></p><p><em>Pediatric population</em></p><p>The safety of ramipril was investigated in 325 children and adolescents aged 2 to 16 years in two clinical trials. While the nature and severity of the side effects are similar to those in adults, the frequency of the following side effects is higher in children:</p><p>Tachycardia, blocked nose and rhinitis, &ldquo;common&rdquo; (i.e. &ge; 1/100 to &lt; 1/10) in the pediatric population, and &ldquo;uncommon&rdquo; (i.e. &ge; 1/1,000 to &lt; 1/100) in adults.</p><p>Conjunctivitis &ldquo;common&rdquo; (i.e. &ge; 1/100 to &lt; 1/10) in the pediatric population and &ldquo;rare&rdquo; (i.e. &ge; 1/10,000 to</p><p>&lt; 1/1,000) in adults.</p><p>Tremor and urticaria &ldquo;uncommon&rdquo; (i.e. &ge; 1/1,000 to &lt; 1/100) in the pediatric population and &ldquo;rare&rdquo; (i.e.</p><p>&ge; 1/10,000 to &lt; 1/1,000) in adults.</p><p>&nbsp;</p><p>The overall safety profile for ramipril in the pediatric population does not differ significantly from the safety profile in adults.</p><p>&nbsp;</p><p><em>Additionally for Amlohope5 mg/5 mg/- 10 mg/5 mg</em></p><p>Allura Red can cause allergic reactions.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Additionally for Amlohope5 mg/10 mg/- 10 mg/10 mg</em></p><p>Azorubine can cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp; </strong><strong>For ramipril </strong><u>Symptoms</u></p><p>Symptoms associated with overdose of ACE inhibitors may include excessive peripheral vasodilatation (with marked hypotension, shock), bradycardia, electrolyte disturbances, and renal failure.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>The patient should be monitored closely and receive symptomatic and supportive therapy. Potential measures include primary detoxification (gastric lavage, administration of adsorbents) and measures to restore hemodynamic stability, such as administration of alpha 1 adrenergic agonists or angiotensin II (angiotensinamide). Ramiprilat, the active metabolite of ramipril is poorly removed from the general circulation by dialysis.</p><p>&nbsp;</p><p>For amlodipine</p><p>There is limited experience with intended overdose in humans.</p><p>&nbsp;</p><p><u>Symptoms</u></p><p>The available data suggest that a prominent overdose can lead to pronounced peripheral vasodilation and possibly to reflex tachycardia. Cases of pronounced and probable persistent systemic hypotension culminating in shock, including shock with fatal outcome, were reported.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>Clinically relevant hypotension due to an overdose of amlodipine requires active support of the cardiovascular system, including close monitoring of heart and lung function, elevation of the extremities and monitoring of fluid balance and urine excretion. A vasoconstrictor can be administered to restore the vascular tone and blood pressure if this is not contraindicated. Intravenously administered calcium gluconate can be beneficial once the effects of calcium channel blockade are reversed.</p><p>&nbsp;</p><p>Gastric lavage can be helpful in certain cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>&nbsp;</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ACE inhibitors and calcium channel blockers ATC code C09BB07</p><p>&nbsp;</p><p>Mechanism of action of ramipril</p><p>Ramiprilat, the active metabolite of the prodrug Ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyzes the</p><p>&nbsp;</p><p>conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation.</p><p>&nbsp;</p><p>Since angiotensin II also stimulates the release of aldosterone, ramiprilat causes a reduction in aldosterone secretion. The average response to ACE inhibitor monotherapy was lower in black (Afro-Caribbean) hypertensive patients (usually a low-renin hypertensive population) than in non-black patients.</p><p>&nbsp;</p><p><u>Pharmacodynamic&nbsp; effects</u></p><p>Administration of ramipril causes a marked reduction in peripheral arterial resistance. Generally, there are no major changes in renal plasma flow and glomerular filtration rate. Administration of ramipril to patients with hypertension leads to a reduction in supine and standing blood pressure without a compensatory rise in heart rate.</p><p>&nbsp;</p><p>In most patients, the onset of the antihypertensive effect of a single dose becomes apparent 1-2 hours after oral administration. The peak effect of a single dose is generally achieved 3-6 hours after oral administration. The antihypertensive effect of a single dose usually lasts for 24 hours.</p><p>&nbsp;</p><p>The maximum antihypertensive effect of continued treatment with ramipril is generally apparent after 3- 4 weeks. It has been shown that the antihypertensive effect is sustained under long-term therapy lasting 2 years.</p><p>&nbsp;</p><p>Abrupt discontinuation of ramipril does not produce a rapid and excessive rebound increase in blood pressure.</p><p>&nbsp;</p><p>Two large randomized, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies showed no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor blockers.</p><p>ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse events. CV death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><em>Pediatric population</em></p><p>In a randomized, double-blind clinical study involving 244 pediatric patients with hypertension (73% primary hypertension), aged 6-16 years, patients received either low dose, medium dose or high dose of ramipril to achieve plasma concentrations of Ramiprilat corresponding to the adult dose range of 1.25 mg,</p><p>5 mg and 20 mg on the basis of body weight. At the end of 4 weeks, ramipril was ineffective in the endpoint of lowering systolic blood pressure but lowered diastolic blood pressure at the highest dose. Both medium and high doses of ramipril showed significant reduction of both systolic and diastolic BP in children with confirmed &nbsp;hypertension.</p><p>&nbsp;</p><p>This effect was not seen in a 4-week, randomized, double-blind dose-escalation study with withdrawal attempt in 218 pediatric patients aged 6-16 years (75% primary hypertension), where both diastolic and systolic blood pressures demonstrated a modest rebound effect but not a statistically significant return to the baseline, This applied for all three dose levels tested (low dose [0.625 mg-2.5 mg], medium dose [2.5 mg- 10 mg] or high dose [5 mg-20 mg] ramipril based on body weight). Ramipril did not have a linear dose/response relation in the pediatric population studied.</p><p>&nbsp;</p><p>Mechanism of action of amlodipine</p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle cells.</p><p>&nbsp;</p><p>The antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle.</p><p>&nbsp;</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24-hour interval. Due to the slow onset of action, no acute drop in blood pressure is expected.</p><p>&nbsp;</p><p>&nbsp;</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids. Amlodipine is also suitable for use in patients with asthma, diabetes or gout.</p><p>&nbsp;</p><p>Use in patients with heart failure</p><p>&nbsp;</p><p>In patients with NYHA class II to IV heart failure, hemodynamic studies and controlled clinical studies showed no clinical deterioration due to amlodipine in the measured parameters, resilience, left ventricular ejection fraction and clinical symptoms. A placebo-controlled study (PRAISE) investigating patients with NYHA grade III and IV heart failure who were treated with digoxin, diuretics and ACE inhibitors showed that amlodipine did not increase the mortality risk or the combined mortality and morbidity in patients with heart failure. In a follow-up, long term, placebo-controlled study (PRAISE-2) of amlodipine tablets in patients with NYHA Grade III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, Amlodipine tablets had no effect on total cardiovascular mortality. In this same population amlodipine tablets were associated with increased reports of pulmonary edema.</p><p>&nbsp;</p><p>&nbsp;</p><p>Treatment to prevent heart attack (ALLHAT) trial</p><p>&nbsp;</p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide diuretic chlorthalidone 12.5-25 mg/d in mild to moderate hypertension. A total of 33,357 hypertensive patients aged 55 or older were randomized and observed for a mean of</p><p>4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI 0.90-1.07 p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs 7.7%, RR 1.38, 95% CI 1.25-1.52 p&lt;0.001).</p><p>However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy (RR 0.96; 95% CI 0.89-1.02 p=0.20).</p><p>&nbsp;</p><p><u>Pediatric population (aged 6 years and over)</u></p><p>In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5 mg dose, and 5 mg dose of amlodipine with placebo, showed that both doses reduced systolic blood pressure significantly more than placebo. The difference between the two doses was not statistically significant.</p><p>The long-term effects of amlodipine on growth, puberty and general development were not investigated. The long-term efficacy of amlodipine in the case of therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood has also not been established.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit study results for Amlohopefor all approved indications in all subgroups of the pediatric population (see information on the pediatric population in section 4.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ramipril</p><p><u>Absorption</u></p><p>Following oral administration ramipril is rapidly resorbed from the gastrointestinal tract: Peak plasma concentrations of ramipril are reached within 1 hour. Based on urinary recovery, the extent of resorption is at least 56% and is not significantly influenced by the presence of food in the gastrointestinal tract. The bioavailability of the active metabolite ramiprilat after oral administration of 2.5 mg and 5 mg ramipril is 45%.</p><p>&nbsp;</p><p>Peak plasma concentrations of ramiprilat, the sole active metabolite of ramipril, are reached 2 to 4 hours after ramipril intake. Steady state plasma concentrations of ramiprilat after once daily dosing with the usual doses of ramipril are reached by about the fourth day of treatment.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Ramipril is almost completely metabolized to ramiprilat, and to the diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Excretion of the metabolites is primarily a renal function.</p><p>&nbsp;</p><p>Plasma concentrations of ramiprilat decline in a polyphasic manner. Because of its potent, saturable binding to ACE and slow dissociation from the enzyme, ramiprilat shows a prolonged terminal elimination phase at very low plasma concentrations.</p><p>&nbsp;</p><p>After multiple once-daily doses of ramipril, the effective half-life of ramiprilat concentrations was 13 to</p><p>17 hours for the 5 to 10 mg doses and longer for the lower 1.25 to 2.5 mg doses. This difference is related to the saturable capacity of the enzyme to bind ramiprilat.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>A single oral 10 mg dose of ramipril produced an undetectable level of ramipril and its metabolite in breast milk. However, the effect of multiple doses is not known.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p><em>Patients with renal impairment (see section 4.2)</em></p><p>Renal excretion of ramiprilat is reduced in patients with impaired renal function, and renal ramiprilat clearance is proportionally related to creatinine clearance. This results in elevated plasma concentrations of ramiprilat, which decrease more slowly than in subjects with normal renal function.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment (see section 4.2)</em></p><p>In patients with impaired liver function, the metabolism of ramipril to ramiprilat was delayed, due to diminished activity of hepatic esterases. The plasma ramipril levels in these patients were increased. Peak plasma concentrations of ramiprilat in these patients, however, are not different from those seen in subjects with normal hepatic function.</p><p>&nbsp;</p><p><em>Pediatric population</em></p><p>The pharmacokinetic profile of ramipril was studied in 30 pediatric hypertensive patients, aged 2-16 years, weighing &ge;10 kg. After doses of 0.05 to 0.2 mg/kg, ramipril was rapidly and extensively metabolized to ramiprilat. Peak plasma concentrations of ramiprilat occurred within 2 to 3 hours. Ramiprilat clearance correlated highly with the logarithm of body weight (p &lt; 0.01) as well as dose (p &lt; 0.001). Clearance and volume of distribution increased with the increasing age of the children for each dose group. The dose of</p><p>0.05 mg/kg in children achieved exposure levels comparable to those in adults treated with ramipril 5 mg. The dose of 0.2 mg/kg in children resulted in exposure levels higher than the maximum recommended dose of 10 mg per day in adults.</p><p>&nbsp;</p><p>Amlodipine</p><p><u>Resorption, distribution and plasma protein binding</u></p><p>Amlodipine is absorbed well after oral administration of therapeutic doses. Peak plasma concentration is achieved 6-12 hours after administration. The absolute bioavailability is approximately 64-80%.</p><p>&nbsp;</p><p>The volume of distribution is 21 l/kg body weight. <em>In vitro </em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>Bioavailability is not influenced by food intake. <u>Biotransformation/elimination</u></p><p>The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily dosing.</p><p>Amlodipine is extensively metabolized by the liver to inactive metabolites. 10% of the parent compound and 60% of the metabolites are excreted in the urine.</p><p>&nbsp;</p><p>Use in the case of hepatic impairment</p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic impairment have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p>&nbsp;</p><p><u>Use in elderly patients</u></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger patients. Amlodipine clearance tends to be decreased in elderly patients, with resulting increases in AUC and elimination half-life. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p>&nbsp;</p><p><u>Use in the pediatric population</u></p><p>A study on population kinetics was conducted in 74 hypertensive children aged from 12 months to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving between 1.25 and 20 mg amlodipine given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For ramipril</p><p>Oral administration of ramipril has been found to be devoid of acute toxicity in rodents and dogs.</p><p>&nbsp;</p><p>Studies involving chronic oral administration have been conducted in rats, dogs and monkeys. Indications of plasma electrolyte shifts and changes in the compositions of the blood were found in all 3 species.</p><p>&nbsp;</p><p>As an expression of the pharmacodynamic activity of ramipril, pronounced enlargement of the juxtaglomerular apparatus was noted in the dog and monkey from daily doses of 250 mg/kg/d. Rats, dogs and monkeys tolerated daily doses of 2, 2.5 and 8 mg/kg/d respectively without side effects. Irreversible kidney damage has been observed in very young rats given a single dose of ramipril.</p><p>&nbsp;</p><p>Reproduction toxicology studies in the rat, rabbit and monkey did not disclose any teratogenic properties. Fertility was not impaired either in male or in female rats.</p><p>The administration of ramipril to female rats during the fetal period and lactation produced irreversible renal damage (dilatation of the renal pelvis) in the offspring at daily doses of 50 mg/kg body weight or higher.</p><p>&nbsp;</p><p>Extensive mutagenicity testing using several test systems has yielded no indication that ramipril possesses mutagenic or genotoxic properties.</p><p>&nbsp;</p><p>For amlodipine</p><p><u>Reproductive toxicity</u></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labor and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans (based on mg/kg).</p><p>&nbsp;</p><p><u>Impairment of fertility</u></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day This corresponds to 8 times the maximum recommended human dose of 10 mg on a mg/m2 basis. In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle- stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>&nbsp;</p><p><u>Carcinogenic/mutagenic&nbsp; potential</u></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice the maximum recommended clinical dose* of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>&nbsp;</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>&nbsp;</p><p>* based on a patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule filling</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Crospovidone (type B) (Ph.Eur.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline &nbsp;cellulose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Glycerol dibehenate (Ph.Eur.)</p><p>&nbsp;</p><p><em>Amlohope5 mg/5 mg</em></p><p><u>Capsule bottom and capsule cap</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Brilliant blue FCF (E133)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Allura red (E129)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p>&nbsp;</p><p><em>Amlohope10 mg/5 mg</em></p><p><u>Capsule bottom</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Iron(III) oxide (E172)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p>&nbsp;</p><p><u>Capsule cap</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Brilliant blue FCF (E133)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Allura red (E129)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p>&nbsp;</p><p><em>Amlohope5 mg/10 mg</em></p><p><u>Capsule bottom</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Iron(III) oxide (E172)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p>&nbsp;</p><p><u>Capsule cap</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Indigo carmine (E132)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Azorubine (E122)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p>&nbsp;</p><p><em>Amlohope10 mg/10 mg</em></p><p><u>Capsule bottom and capsule cap</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Indigo carmine (E132)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Azorubine (E122)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide (E171)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Amlohope after the expiry date which is stated on the carton {year/month) date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not use Amlohope if you notice the visible signs (e.g. discoloration) of deterioration.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>unmarked self-closing Coni Snap type, size 3, hard gelatin capsules with opaque, amethyst coloured body and opaque amethyst coloured cap. filled with white or almost white, odourless or almost odourless granular powder, free of mechanical impurities.</p><p>&nbsp;</p><p>Amlohope, 10 mg/5 mg, hard capsules:</p><p>unmarked self-closing Coni Snap type, size 0, hard gelatin capsules with opaque, flesh coloured body and opaque, amethyst coloured cap filled with white or almost white, odourless or almost odourless granular powder, free of mechanical impurities.</p><p>Amlohope, 5 mg/10 mg, hard capsules:</p><p>unmarked self-closing Coni Snap type, size 0, hard gelatin capsules with opaque, flesh coloured body and opaque maroon coloured cap filled with white or almost white, odourless or almost odourless granular powder, free of mechanical impurities.</p><p>Amlohope, 10 mg/10 mg, hard capsules:</p><p>unmarked self-closing Coni Snap type, size 0, hard gelatin capsules with opaque, maroon coloured body and opaque maroon coloured cap filled with white or almost white, odourless or almost odourless granular powder, free of mechanical impurities.</p><p>&nbsp;</p><p><em>Package:</em></p><p>10, 20, 30, 50 or 100 hard capsules in blister packs, in carton box. Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unused medicinal product or waste material should be disposed of in accordance with national regulations</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hexal AG 
Industriestraße 25
83607 Holzkirchen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>